How much did CureVac achieve in EBIT for the current year?
In the current year, CureVac has achieved an EBIT of 194.96 M EUR.
CureVac EBIT 2024
CureVac EBIT
194.96 M EUR
Ticker
CVAC
ISIN
NL0015436031
WKN
A2P71U
In 2024, CureVac's EBIT was 194.96 M EUR, a -172.29% increase from the -269.69 M EUR EBIT recorded in the previous year.
The CureVac EBIT history
| YEAR | EBIT (undefined EUR) |
|---|---|
| 2029e | 107.22 |
| 2028e | 55.55 |
| 2027e | 77.49 |
| 2026e | -90.85 |
| 2025e | -118.01 |
| 2024e | 194.96 |
| 2023 | -269.69 |
| 2022 | -225 |
| 2021 | -478.7 |
| 2020 | -109.8 |
| 2019 | -99.5 |
| 2018 | -72.8 |
CureVac Revenue, EBIT, Net Income NL0015436031 · A2P71U
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into CureVac, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by CureVac from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects CureVac’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of CureVac. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into CureVac’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing CureVac’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on CureVac’s growth potential.
CureVac Revenue, EBIT and net profit per share
| Date | CureVac Revenue | CureVac EBIT | CureVac Net Income |
|---|---|---|---|
| 2029e | 254.83 M undefined | 107.22 M undefined | -124.14 M undefined |
| 2028e | 198.86 M undefined | 55.55 M undefined | -121.83 M undefined |
| 2027e | 216.63 M undefined | 77.49 M undefined | 187.57 M undefined |
| 2026e | 119.02 M undefined | -90.85 M undefined | -64.07 M undefined |
| 2025e | 56.83 M undefined | -118.01 M undefined | -116.32 M undefined |
| 2024e | 286.1 M undefined | 194.96 M undefined | 102.21 M undefined |
| 2023 | 53.76 M undefined | -269.69 M undefined | -260.17 M undefined |
| 2022 | 67.4 M undefined | -225 M undefined | -249 M undefined |
| 2021 | 103 M undefined | -478.7 M undefined | -411.7 M undefined |
| 2020 | 48.9 M undefined | -109.8 M undefined | -129.1 M undefined |
| 2019 | 17.4 M undefined | -99.5 M undefined | -99.9 M undefined |
| 2018 | 12.9 M undefined | -72.8 M undefined | -71.2 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2018 | 12.9 M EUR | -72.8 M EUR | -71.2 M EUR |
| 2019 | 17.4 M EUR | -99.5 M EUR | -99.9 M EUR |
| 2020 | 48.9 M EUR | -109.8 M EUR | -129.1 M EUR |
| 2021 | 103 M EUR | -478.7 M EUR | -411.7 M EUR |
| 2022 | 67.4 M EUR | -225 M EUR | -249 M EUR |
| 2023 | 53.76 M EUR | -269.69 M EUR | -260.17 M EUR |
| 2024e | 286.1 M EUR | 194.96 M EUR | 102.21 M EUR |
| 2025e | 56.83 M EUR | -118.01 M EUR | -116.32 M EUR |
| 2026e | 119.02 M EUR | -90.85 M EUR | -64.07 M EUR |
| 2027e | 216.63 M EUR | 77.49 M EUR | 187.57 M EUR |
| 2028e | 198.86 M EUR | 55.55 M EUR | -121.83 M EUR |
| 2029e | 254.83 M EUR | 107.22 M EUR | -124.14 M EUR |
CureVac stock margins NL0015436031 · A2P71U
The CureVac margin analysis displays the gross margin, EBIT margin, as well as the profit margin of CureVac. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for CureVac.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the CureVac's sales revenue. A higher gross margin percentage indicates that the CureVac retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the CureVac's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the CureVac's total revenue generated. When comparing the revenue margin year over year, investors can gauge the CureVac's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the CureVac. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the CureVac's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
CureVac Margin History
| CureVac Gross margin | CureVac Profit margin | CureVac EBIT margin | CureVac Profit margin |
|---|---|---|---|
| 2029e | -116.3 % | 42.08 % | -48.71 % |
| 2028e | -116.3 % | 27.93 % | -61.26 % |
| 2027e | -116.3 % | 35.77 % | 86.59 % |
| 2026e | -116.3 % | -76.33 % | -53.83 % |
| 2025e | -116.3 % | -207.67 % | -204.69 % |
| 2024e | -116.3 % | 68.14 % | 35.73 % |
| 2023 | -116.3 % | -501.67 % | -483.96 % |
| 2022 | -135.91 % | -333.83 % | -369.44 % |
| 2021 | -131.26 % | -464.76 % | -399.71 % |
| 2020 | 70.96 % | -224.54 % | -264.01 % |
| 2019 | -60.92 % | -571.84 % | -574.14 % |
| 2018 | -37.98 % | -564.34 % | -551.94 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2018 | -37.98 % | -564.34 % | -551.94 % |
| 2019 | -60.92 % | -571.84 % | -574.14 % |
| 2020 | 70.96 % | -224.54 % | -264.01 % |
| 2021 | -131.26 % | -464.76 % | -399.71 % |
| 2022 | -135.91 % | -333.83 % | -369.44 % |
| 2023 | -116.3 % | -501.67 % | -483.96 % |
| 2024e | -116.3 % | 68.14 % | 35.73 % |
| 2025e | -116.3 % | -207.67 % | -204.69 % |
| 2026e | -116.3 % | -76.33 % | -53.83 % |
| 2027e | -116.3 % | 35.77 % | 86.59 % |
| 2028e | -116.3 % | 27.93 % | -61.26 % |
| 2029e | -116.3 % | 42.08 % | -48.71 % |
CureVac Aktienanalyse
What does CureVac do?
CureVac NV is a German biotechnology company that was founded in 2000 by Ingmar Hoerr, who still leads the company today. The company is headquartered in Tübingen and has a branch in Frankfurt am Main. CureVac's goal is to develop and produce innovative therapies to combat diseases. The history of CureVac began with a focus on the development of RNA-based therapeutics. RNA is a molecule that plays a central role in protein production within the cell. By using RNA in therapeutic applications, the body's own processes can be utilized to fight diseases. CureVac has successfully developed a variety of RNA-based therapeutics in recent years, which are in various stages of clinical development. CureVac's business model is based on providing its technology platform to other companies. These companies can use the platform to develop their own RNA-based therapeutics. CureVac receives fees for this service and also receives a share of any revenues resulting from these projects. CureVac also operates its own pipeline of therapeutic products based on various technologies. One important technology, for example, is the use of messenger RNA (mRNA) to produce proteins that can have a therapeutic effect. CureVac has entered into several partnerships with large pharmaceutical companies such as Sanofi and Boehringer Ingelheim to bring its products to market. The company benefits from the strength of its technology platform and its ability to develop new methods for the production of RNA-based therapeutics. Furthermore, CureVac has played an important role in containing the global COVID-19 pandemic. The company has developed an mRNA vaccine against the SARS-CoV-2 virus, which is approved in Europe. The vaccine has shown to be particularly effective and has a high efficacy against the various variants of the virus. CureVac has signed a contract with the European Union for the delivery of up to 405 million doses of its COVID-19 vaccine, making it an important partner in the fight against the pandemic. Overall, CureVac is a company with a strong focus on RNA-based therapeutics. The company has successfully built a strong technology platform in recent years, enabling other companies to develop their own RNA-based therapeutics. At the same time, CureVac has built its own pipeline of products in various stages of clinical development. The company benefits from the strength of its technology platform and its ability to develop sustainable and effective solutions for various diseases. The success of CureVac, particularly its role in the fight against the COVID-19 pandemic, has shown that RNA technology will play an important role in the future of biotechnology. CureVac ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing CureVac's EBIT
CureVac's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of CureVac's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
CureVac's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in CureVac’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about CureVac stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company CureVac.
How has the EBIT of CureVac developed in recent years?
The EBIT of CureVac has increased by -172.291% decreased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company CureVac?
The EBIT of CureVac is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does CureVac pay?
Over the past 12 months, CureVac paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, CureVac is expected to pay a dividend of 0 EUR.
What is the dividend yield of CureVac?
The current dividend yield of CureVac is .
When does CureVac pay dividends?
CureVac pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of CureVac?
CureVac paid dividends every year for the past 0 years.
What is the dividend of CureVac?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is CureVac located?
CureVac is assigned to the 'Health' sector.
Wann musste ich die Aktien von CureVac kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of CureVac from 12/18/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 12/18/2024.
When did CureVac pay the last dividend?
The last dividend was paid out on 12/18/2024.
What was the dividend of CureVac in the year 2023?
In the year 2023, CureVac distributed 0 EUR as dividends.
In which currency does CureVac pay out the dividend?
The dividends of CureVac are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The CureVac stock can be added to a savings plan with the following providers: Scalable Capital
Andere Kennzahlen von CureVac
Our stock analysis for CureVac Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CureVac Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
